<DOC>
	<DOCNO>NCT00001328</DOCNO>
	<brief_summary>Malignant brain tumor responsible significant amount death child adult . Even advance surgery , radiation therapy , chemotherapy , many patient diagnose malignant brain tumor survive month week . In attempt improve prognosis patient , researcher develop new approach brain tumor therapy . This approach make use DNA technology transfer gene sensitive therapy cell tumor . Infections herpes simplex virus cause cold sore area mouth . A drug call ganciclovir ( Cytovene ) kill virus . Ganciclovir effective herpes virus contain gene ( Herpes-Thymidine Kinase TK gene ) sensitive drug . Researchers able separate gene virus . Using DNA technology , researcher hope transfer implant TK gene tumor cell make sensitive ganciclovir . In theory , give patient ganciclovir kill tumor cell TK gene incorporate .</brief_summary>
	<brief_title>Gene Therapy Treatment Brain Tumors</brief_title>
	<detailed_description>Malignant brain tumor responsible significant morbidity mortality pediatric adult population . These common tumor present enormous therapeutic challenge due poor outcome despite radical surgery , high dose radiotherapy chemotherapy . Survival patient time diagnosis measure month recurrence treatment associate life expectancy week . In attempt improve grim prognosis patient malignant brain tumor ( primary tumor secondary metastasis systemic cancer melanoma , lung breast cancer ) , develop novel approach therapy brain tumor . This approach make use recombinant DNA technology transfer sensitivity gene brain tumor . This achieve direct injection tumor cell line actively produce retroviral vector carry gene confer drug sensitivity tumor . A retroviral vector mouse retrovirus genetically engineer replace gene new gene . Such vector capable `` infecting '' mammalian cell stably incorporate new genetic material genome infect host . The producer cell NIH 3T3 cell genetically engineer continually produce retroviral vector . The new gene incorporate genome tumor cell express protein encode new gene . This protein ( herpes simplex virus enzyme thymidine kinase , HS-tk ) sensitize tumor cell antiviral drug ( ganciclovir , GCV ) natural substrate HS-tk . The enzymatic process induce GCV lead death natural substrate HS-tk . The enzymatic process induce GCV lead death cell express herpes TK activity , i.e. , death tumor cell . Since HS-tk enzyme normally present mammalian cell low affinity GCV , systemic toxicity relate mechanism observe . This type vivo gene transfer several unique feature . First , retroviral-vectors integrate express gene cell actively synthesize DNA . Therefore , surround non-proliferating normal brain tissue acquire HS-tk gene remain insensitive GCV . Second , transduce tumor cell ( retroviral vector produce cell ) kill host immune response and/or GCV treatment eliminate potential concern insertional mutagenesis give rise malignant cell . This first clinical attempt treat malignant tumor human being in-vivo genetic manipulation tumor 's genome .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>INCLUSION CRITERIA : All adult , great 18 year age , malignant brain tumor ( primary metastatic ) fail standard therapy disease eligible enter study . EXCLUSION CRITERIA : No pregnant woman enter study . Patients HIV infection accept study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 30, 2010</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Gene Transfer</keyword>
	<keyword>Recurrent Tumors</keyword>
	<keyword>Primary Tumors</keyword>
	<keyword>Metastases</keyword>
	<keyword>Anti-Viral Drugs</keyword>
	<keyword>Chemosensitization</keyword>
	<keyword>Brain Tumors</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Ganciclovir</keyword>
</DOC>